



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

29.05.2024

To,  
Corporate Services Department,  
BSE Ltd.,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai- 400001

Dear Sir,

**Sub: Outcome Of Board Meeting For The Approval of Audited Financial Results For The Fourth Quarter And Year Ended 31<sup>st</sup> March, 2024 And Recommendation Of Dividend**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Wednesday 29<sup>th</sup> May, 2024**, at the office of company, have inter-alia approved the Standalone and Consolidated Audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2024.

In terms of the Provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Audited Standalone financial results of the Company for the quarter and year ended 31<sup>st</sup> March, 2024 along with the Audit Report on the standalone financial statements.
2. Audited Consolidated financial results of the Company for the quarter and year ended 31<sup>st</sup> March, 2024 along with the Audit Report on the consolidated financial statements.
3. Declaration that the statutory auditors have Issued audit reports with unmodified opinion on financial statements.

Further, the Board of Directors have recommended a dividend of Rs. 2.00/- (Two Rupees Only) per equity share for the Financial Year ended on 31<sup>st</sup> March, 2024. The said dividend, if declared at the ensuing Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws.



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

The meeting of Board of Directors commenced at 02:00 P.M. and concluded at 03:40 P.M.

The above information will be available on the website of the company i.e <https://titanbiotechltd.com> and BSE Ltd i.e [www.bseindia.com](http://www.bseindia.com) .

Request to kindly take this information on record and acknowledge.

**For and on behalf of  
Titan Biotech Limited**



**Charanjit Singh  
Company Secretary & Complince Officer  
M.No A12726**

**Encl: As above**



# TITAN BIOTECH LIMITED



AN ISO 9001:205 CERTIFICATED COMPANY

Corporate Office: 903-909, 9th Floor, Bigjos Tower, Netaji Subash Place, Delhi-110034, India  
Tel.: 011-27355742, 71239900 | CIN L74999RJ1992PLC013387

To,  
Corporate Services Department,  
BSE Ltd.,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai- 400001

Date: 29.05.2024

Dear Ma'am/Sir,

**Scrip Code: 524717**

**Sub: Declaration Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Unmodified Opinion**

I, Prem Shankar Gupta, Chief Financial Officer of Titan Biotech Limited hereby confirm and declare that the Statutory Auditors of the Company, M/s A N S K & Associates, Chartered Accountants (Firm Registration No. 026177N), have not expressed any modified opinion in their Audit Report pertaining to Annual Audited Financial Results (Standalone & Consolidated) of the Company for the financial year ended 31<sup>st</sup> March, 2024.

This declaration is given in compliance with Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/56/2016 dated May, 27, 2016 and SEBI vide Notification No. SEBI/LAD-NRO/GN/2016-17 /001 dated May 25, 2016.

Kindly take the above in your record.

For and on behalf of  
Titan Biotech Limited

**Prem Shankar Gupta**  
Chief Financial Officer



## **INDEPENDENT AUDITOR'S REPORT**

### **TO THE BOARD OF DIRECTORS OF TITAN BIOTECH LIMITED**

#### **Report on the audit of the Standalone Financial Results**

#### **Opinion**

We have audited the accompanying standalone quarterly financial results of Titan Biotech Limited (the company) for the quarter and year ended March 31, 2024 ("Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. Gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2024.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Management's Responsibilities for the Standalone Financial Results**

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.



This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matter**

The standalone annual financial results include the results for the quarter ended 31 March 2024 being the balancing figure between the audited figures in respect of the full financial year and the published audited year to date figures up to the third quarter of the current financial year.

**For A N S K & Associates,**  
Chartered Accountants  
FRN - 026177N

**Akhil**  
Digitally signed  
by Akhil Mittal  
Date: 2024.05.29  
14:19:18 +05'30'  
**Mittal**

(CA Akhil Mittal)  
Partner

Membership No. – 517856

UDIN: **24517856BKHCCJ8506**

Date: May 29, 2024

Place: Delhi



## **INDEPENDENT AUDITOR'S REPORT**

### **TO THE BOARD OF DIRECTORS OF TITAN BIOTECH LIMITED**

#### **Report on the audit of the Consolidated Financial Results**

##### **Opinion**

We have audited the accompanying consolidated annual financial results of Titan Biotech Limited (hereinafter referred to as the "Holding Company") and its share of the net profit after tax and total comprehensive income its associate for the year ended 31 March 2024, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate/ consolidated audited financial statements /financial information of the Associate, the aforesaid consolidated annual financial results:

- i. include the annual financial results of the following: Peptech Biosciences Limited (Associate), Titan Media Limited (Associate)
- ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- iii. Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2024.

##### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results section of our report. We are independent of the Group, its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of the other auditors referred to in paragraph (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.



### **Management's Responsibilities for the Consolidated Financial Results**

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit loss and other comprehensive income and other financial information of the Group including its associate in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group and the respective Management and Board of Directors, of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group and the respective Management and Board of Directors, of its associate are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group and the respective Management and Board of Directors, of its associate is responsible for overseeing the financial reporting process of each company.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional





omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associate and to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements/financial information of the entities within the Group and its associate to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements/financial information of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in paragraph (a) of the Other Matters paragraph in this audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.



**A N S K & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**  
**OFFICE :414, RG Trade Tower, NetajiSubhash Place**  
**Pitampura, New Delhi-110034**  
**OFFICE NO. -011-46010089**  
**EMAIL :amccorporateservices@gmail.com**

---

### **Other Matter**

- a) The consolidated audited annual financial results include the Group's share of total net profit after tax of Rs. 118.98 lakh and total comprehensive income of Rs. 118.98.lakh for the year ended 31 March 2024, as considered in the consolidated annual financial results, in respect of 2 associates. These audited financial statements/ financial information have been audited/reviewed by us.
- b) The consolidated annual financial results include the results for the quarter ended 31 March 2024 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

**For A N S K & Associates,**  
Chartered Accountants  
FRN - 026177N

Akhil  
Mittal

Digitally signed by  
Akhil Mittal  
Date: 2024.05.29  
14:17:58 +05'30'

(CA Akhil Mittal)  
Partner

Membership No. – 517856

UDIN: **24517856BKHCCI3892**

Date: May 29, 2024

Place: Delhi

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2024**

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	STANDALONE				
		QUARTER ENDED			YEAR ENDED	
		31.03.2024 AUDITED	31.12.2023 UNAUDITED	31.03.2023 AUDITED	31.03.2024 AUDITED	31.03.2023 AUDITED
<b>1</b>	<b>INCOME</b>					
	Revenue from operations					
	Other Income	3,991.87	4,597.89	3,683.63	16,407.21	14,399.93
	<b>Total Income</b>	<b>4,039.59</b>	<b>4,641.59</b>	<b>3,732.83</b>	<b>16,582.03</b>	<b>14,594.26</b>
<b>2</b>	<b>EXPENSES</b>					
	Cost of Materials Consumed	2,124.67	2,028.23	1,728.01	8,089.24	7,080.54
	Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(296.07)	124.98	8.85	(528.63)	(93.21)
	Employee Benefit Expenses	680.38	602.34	522.08	2,371.06	1,820.90
	Finance Costs	34.08	26.37	25.71	117.00	74.59
	Depreciation and Amortization Expenses	84.00	83.48	71.08	333.06	260.03
	Other Expenses	775.05	782.14	741.48	3,047.40	2,639.80
	<b>Total Expenses</b>	<b>3,402.11</b>	<b>3,647.54</b>	<b>3,097.21</b>	<b>13,429.13</b>	<b>11,782.65</b>
<b>3</b>	<b>Profit/(Loss) before exceptional items and tax (1-2)</b>					
		637.48	994.05	635.62	3,152.90	2,811.61
<b>4</b>	<b>Exceptional Items</b>					
<b>5</b>	<b>Profit/ (loss) before tax (3+4)</b>					
<b>6</b>	<b>Tax expense:</b>					
	(I) Current Tax	147.34	254.23	177.93	778.87	721.44
	(II) Deferred Tax	6.02	1.47	(6.67)	10.61	(8.89)
	(III) Earlier year taxes	-	-	-	(2.90)	(3.43)
	<b>Total Tax (I+II)</b>	<b>153.36</b>	<b>255.70</b>	<b>171.26</b>	<b>786.58</b>	<b>709.12</b>
<b>7</b>	<b>Profit (Loss) for the period after Tax (5-6)</b>					
		<b>484.12</b>	<b>738.35</b>	<b>464.36</b>	<b>2,366.32</b>	<b>2,102.49</b>
<b>8</b>	<b>Other comprehensive income (Net of Tax)</b>					
	Items that will not be reclassified to profit or loss					
A.	(i) Re-measurement gain on defined benefit plans	17.13	2.07	8.31	23.36	8.31
	(ii) Income tax relating to these items	(4.31)	(0.52)	(2.09)	(5.88)	(2.09)
B.	Items that will be reclassified to profit or loss					
	(i) Income tax relating to these items					
	<b>Total Other Comprehensive Income for the period (A+B) (net of taxes)</b>	<b>12.82</b>	<b>1.55</b>	<b>6.22</b>	<b>17.48</b>	<b>6.22</b>
<b>9</b>	<b>Total Comprehensive Income for the period (7+8)</b>					
		<b>496.94</b>	<b>739.90</b>	<b>470.58</b>	<b>2,383.80</b>	<b>2,108.71</b>
<b>10</b>	<b>Paid-up equity share capital (Face Value of Rs. 10/- each)</b>					
		<b>826.37</b>	<b>826.37</b>	<b>826.37</b>	<b>826.37</b>	<b>826.37</b>
<b>11</b>	<b>Other Equity</b>					
					<b>12,017.85</b>	<b>9,782.79</b>
<b>12</b>	<b>Earnings per equity share (face value of Rs. 10/- each) not annualised</b>					
	(1) Basic	5.86	8.93	5.62	28.64	25.44
	(2) Diluted	5.86	8.93	5.62	28.64	25.44

**Notes:**

- The above audited standalone financial results for the quarter and year ended on 31.03.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on May 29, 2024. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter and year ended March 31, 2024, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31st March, 2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 63.90 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- The Board of Directors of the company has recommended a dividend of Rs. 2.00 per equity share for the financial year ended on 31st March, 2024. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.
- The Statutory Auditors have carried out audit of the financial results for the quarter and year ended on 31.03.2024

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448



Place : Delhi  
Dated : 29.05.2024

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2024**

(Rs. IN LAKHS) except for EPS


Sr. No.	PARTICULARS	STANDALONE				
		QUARTER ENDED			YEAR ENDED	YEAR ENDED
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
	AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	
1	Total Income from Operations (Net)	4,039.59	4,641.59	3,732.83	16,582.03	14,594.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	637.48	994.05	635.62	3,152.90	2,811.61
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	637.48	994.05	635.62	3,152.90	2,811.61
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	484.12	738.35	464.36	2,366.32	2,102.49
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period(after tax) and Other Comprehensive income(after tax)(refer note 3)	496.94	739.90	470.58	2,383.80	2,108.71
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	12,017.85	9,782.79
8	Earning Per Share (of INR 10/- each)					
	(a) Basic	5.86	8.93	5.62	28.64	25.44
	(b) Diluted	5.86	8.93	5.62	28.64	25.44

**NOTES :**

- The above is an extract of the detailed format of standalone audited Financial Results for the quarter and year ended on 31.03.2024 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone audited Financial Results for the said quarter and year ended on 31.03.2024 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com. The statutory auditors of the company have carried out a limited review of the aforesaid results.
- The above audited standalone financial results for the quarter and year ended on 31.03.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on May 29, 2024. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter and year ended March 31, 2024, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter year ended on 31.03.2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone audited financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 63.90 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- The Board of Directors of the company has recommended a dividend of Rs. 2.00 per equity share for the financial year ended on 31st March, 2024. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.
- The Statutory Auditors have carried out audit of the financial results for the quarter and year ended on 31.03.2024

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448



Place : Delhi  
Dated : 29.05.2024


**TITAN BIOTECH LIMITED**  
Standalone Balance Sheet as at 31st March, 2024

(Rs. in Lakhs.)

Particulars	As at	
	31/03/2024 Audited	31/03/2023 Audited
<b>I ASSETS</b>		
<b>1. Non-Current Assets</b>		
a. Property, Plant and Equipment	4,262.55	2,620.57
b. Capital Work-in-Progress	253.21	1,329.40
c. Right of use Assets	931.21	960.39
d. Intangible assets	7.22	8.52
e. Intangible assets under development	2.28	
f. Financial Assets		
(i) Investments	2,318.33	1,158.62
(ii) Other Financial Assets	164.87	161.52
<b>Total Non-current assets</b>	<b>7,939.67</b>	<b>6,239.02</b>
<b>2. Current Assets</b>		
a. Inventories	4,557.10	3,616.96
b. Financial Assets		
(i) Trade receivables	1,865.79	2,100.77
(ii) Cash and cash equivalents	284.01	486.37
c. Current Tax Assets (Net)	5.28	-
d. Other Current Assets	505.23	626.46
<b>Total Current assets</b>	<b>7,217.41</b>	<b>6,830.56</b>
<b>TOTAL ASSETS</b>	<b>15,157.08</b>	<b>13,069.58</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>A Equity</b>		
a. Equity Share Capital	826.37	826.37
b. Other Equity	12,017.84	9,782.79
<b>TOTAL EQUITY</b>	<b>12,844.21</b>	<b>10,609.16</b>
<b>B Liabilities</b>		
<b>1. Non-Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	45.33	29.90
(ii) Lease liabilities	69.44	113.21
b. Deferred tax liabilities (Net)	137.24	120.75
c. Provisions	148.34	161.51
<b>Total Non-Current Liabilities</b>	<b>400.35</b>	<b>425.37</b>
<b>2. Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	671.76	669.96
(ii) Lease liabilities	43.76	38.10
(iii) Trade payables		
(a) Total outstanding dues of micro enterprise and small enterprises	55.65	-
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	281.17	554.97
(iv) Other financial liabilities	565.73	493.10
b. Other current liabilities	238.81	242.84
c. Provisions	55.64	33.21
d. Current Tax Liabilities (Net)	-	2.88
<b>Total Current Liabilities</b>	<b>1,912.52</b>	<b>2,035.06</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>15,157.08</b>	<b>13,069.58</b>

For Titan Biotech Limited

*Naresh Kumar Singla*  
[Naresh Kumar Singla]  
Managing Director  
DIN-00027448



Place : Delhi  
Date : 29.05.2024

**TITAN BIOTECH LIMITED**  
**Standalone Cash Flow Statement for the period ended on 31st March, 2024**

(Rs. in Lakhs.)

Particulars	Year ended	Year ended
	31/03/2024	31/03/2023
	Audited	Audited
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before Tax	3,152.90	2,811.61
<b>Adjustment for :</b>		
Finance Costs	117.00	74.59
Provisions	32.63	31.23
Earlier year Taxes	2.90	3.43
Depreciation and Amortization Expenses	333.06	260.03
Operating profit before working capital changes	3,638.49	3,180.89
Changes in working Capital:		
Inventories	(940.15)	(148.98)
Trade and other Receivables	352.87	(493.99)
Trade and other Payables	(149.55)	329.86
Cash generation from Operation	2,901.66	2,867.78
Payment of Direct Taxes	(787.03)	(749.95)
<b>Net Cash generated/ (used) - Operating Activities</b>	<b>2,114.63</b>	<b>2,117.83</b>
<b>B. CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Purchase of Investment in shares	(1,159.71)	(755.50)
Purchase of Fixed Assets (incl.Capital WIP)	(899.84)	(1,290.46)
Right of use assets	29.18	(26.55)
<b>Net Cash Generated/ (Used) - Investing Activities</b>	<b>(2,030.37)</b>	<b>(2,072.51)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Repayment of Long-term Borrowings	15.44	(78.22)
Repayment of Lease Liabilities	(38.11)	11.49
Proceeds/(Repayment) of Short-term Borrowings (Net)	1.80	24.94
Finance Cost paid	(117.00)	(74.59)
Dividend paid	(148.75)	(123.96)
<b>Net Cash Generated/ (Used) - Financing Activities</b>	<b>(286.62)</b>	<b>(240.34)</b>
<b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b>	<b>(202.36)</b>	<b>(195.02)</b>
Add : Opening Cash and Cash Equivalents	486.37	681.39
<b>Closing Cash and Cash Equivalents</b>	<b>284.01</b>	<b>486.37</b>


**Notes:**

- The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

Place : Delhi  
Date : 29.05.2024

For Titan Biotech Limited

  
**[Naresh Kumar Singla]**  
**Managing Director**  
**DIN-00027448**



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A, RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239980, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2024**

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED	YEAR ENDED
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
	AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	
1	<b>INCOME</b>					
	Revenue from operations	3,991.87	4,597.89	3,683.63	16,407.21	14,399.93
	Other Income	47.72	43.70	49.20	174.82	194.33
	<b>Total Income</b>	<b>4,039.59</b>	<b>4,641.59</b>	<b>3,732.83</b>	<b>16,582.03</b>	<b>14,594.26</b>
2	<b>EXPENSES</b>					
	Cost of Materials Consumed	2,124.67	2,028.23	1,728.01	8,089.24	7,080.54
	Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	(296.07)	124.98	8.85	(528.63)	(93.21)
	Employee Benefit Expenses	680.38	602.34	522.08	2,371.06	1,820.90
	Finance Costs	34.08	26.37	25.71	117.00	74.59
	Depreciation and Amortization Expenses	84.00	83.48	71.08	333.06	260.03
	Other Expenses	775.05	782.14	741.48	3,047.40	2,639.80
	<b>Total Expenses</b>	<b>3,402.11</b>	<b>3,647.54</b>	<b>3,097.21</b>	<b>13,429.13</b>	<b>11,782.65</b>
3	<b>Profit/(loss) before exceptional items and tax (1-2)</b>	<b>637.48</b>	<b>994.05</b>	<b>635.62</b>	<b>3,152.90</b>	<b>2,811.61</b>
4	Exceptional Items					
5	<b>Profit/ (loss) before tax (3+4)</b>	<b>637.48</b>	<b>994.05</b>	<b>635.62</b>	<b>3,152.90</b>	<b>2,811.61</b>
6	Tax expense:					
	(I) Current Tax	147.34	254.23	177.93	778.87	721.44
	(II) Earlier year taxes	-	-	-	(2.90)	(3.43)
	(III) Deferred Tax	6.02	1.47	(6.67)	10.61	(8.89)
	<b>Total Tax (I+II)</b>	<b>153.36</b>	<b>255.70</b>	<b>171.26</b>	<b>786.58</b>	<b>709.12</b>
7	<b>Profit (Loss) for the period after Tax (5-6)</b>	<b>484.12</b>	<b>738.35</b>	<b>464.36</b>	<b>2,366.32</b>	<b>2,102.49</b>
8	<b>Share in Profit of Associate</b>	<b>15.51</b>	<b>(20.88)</b>	<b>30.76</b>	<b>118.98</b>	<b>381.93</b>
9	<b>Profit (Loss) for the period (7+8)</b>	<b>499.63</b>	<b>717.47</b>	<b>495.12</b>	<b>2,485.30</b>	<b>2,484.42</b>
10	<b>Other comprehensive income (Net of Tax)</b>					
	Items that will not be reclassified to profit or loss					
A	(i) Re-measurement gain on defined benefit plans	17.13	2.07	8.31	23.36	8.31
	(ii) Income tax relating to these items	(4.31)	(0.52)	(2.09)	(5.88)	(2.09)
B	Items that will be reclassified to profit or loss					
	(i) Income tax relating to these items					
	<b>Total Other Comprehensive Income for the period (A+B) (net of taxes)</b>	<b>12.82</b>	<b>1.55</b>	<b>6.22</b>	<b>17.48</b>	<b>6.22</b>
11	<b>Total Comprehensive Income for the period (7+8)</b>	<b>512.45</b>	<b>719.02</b>	<b>501.34</b>	<b>2,502.78</b>	<b>2,490.64</b>
12	<b>Net profit attributable to:</b>					
	Owners of the holding company					
	Non-controlling interest					
13	<b>Other comprehensive income attributable to :</b>					
	Owners of the holding company					
	Non-controlling interest					
14	<b>Total Comprehensive Income attributable to (10+11)</b>					
	Owners of the holding company					
	Non-controlling interest					
15	<b>Paid-up equity share capital (Face Value of Rs. 10/- each)</b>	<b>826.37</b>	<b>826.37</b>	<b>826.37</b>	<b>826.37</b>	<b>826.37</b>
16	<b>Other Equity</b>				<b>12,529.20</b>	<b>10,164.72</b>
17	<b>Earnings per equity share (face value of Rs.10/- each) not annualised</b>					
	(1) Basic	6.05	8.68	5.99	30.07	30.06
	(2) Diluted	6.05	8.68	5.99	30.07	30.06

**Notes:**

- The above consolidated audited financial results for the quarter and year ended on 31.03.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on May 29, 2024. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter and year ended March 31, 2024, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The consolidated audited financial results for the quarter and year ended on 31.03.2024 include the results of following- Associate Company - Peptech Biosciences Limited and Titan Media Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31 March, 2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 63.90 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- The Board of Directors of the company has recommended a dividend of Rs. 2.00 per equity share for the financial year ended on 31st March, 2024. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448



Place : Delhi  
Dated :29.05.2024

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2024**

(Rs. IN LAKHS) except for EPS


Sr. No	PARTICULARS	CONSOLIDATED				
		QUARTER ENDED			YEAR ENDED	YEAR ENDED
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023
		AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED
1	Total Income from Operations (Net)	4,039.59	4,641.59	3,732.83	16,582.03	14,594.26
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	637.48	994.05	635.62	3,152.90	2,811.61
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	637.48	994.05	635.62	3,152.90	2,811.61
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	499.63	717.47	495.12	2,485.30	2,484.42
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3)	512.45	719.02	501.34	2,502.78	2,490.64
6	Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)	826.37	826.37	826.37	826.37	826.37
7	Other Equity excluding Revaluation Reserves as per the balance sheet	-	-	-	12,529.20	10,164.72
8	Earning Per Share (of INR 10/- each)					
	(a) Basic	6.05	8.68	5.99	30.07	30.06
	(b) Diluted	6.05	8.68	5.99	30.07	30.06

**NOTES :**

- The above is an extract of the detailed format of consolidated audited Financial Results for the quarter and year ended on 31.03.2024 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations, 2015. The full format of the consolidated audited Financial Results for the said quarter and year ended on 31st March 2024 are available on the website of BSE Limited at [www.bseindia.com](http://www.bseindia.com) and on company website at [www.titanbiotechltd.com](http://www.titanbiotechltd.com).
- The above consolidated audited financial results for the quarter and year ended on 31.03.2024 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on May 29, 2024. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter and year ended on 31.03.2024 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ( ' Ind AS ' ) specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.
- During the year, the company paid Rs. 63.90 Lakhs towards Corporate Social Responsibility (CSR) expenditure.
- The Board of Directors of the company has recommended a dividend of Rs. 2.00 per equity share for the financial year ended on 31st March, 2024. The Dividend will be paid after approval of the same by shareholders in the Annual General meeting.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

*Naresh Kumar Singla*  
NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448



Place : Delhi  
Dated :29.05.2024




**TITAN BIOTECH LIMITED**  
**Consolidated Balance Sheet as at 31st March, 2024**

(Rs. in Lakhs.)

Particulars	As at	
	31/03/2024 Audited	31/03/2023 Audited
<b>I ASSETS</b>		
<b>1. Non-Current Assets</b>		
a. Property, Plant and Equipment	4,262.55	2,620.57
b. Capital Work-in-Progress	253.21	1,329.40
c. Right of use Assets	931.21	960.39
d. Intangible assets	7.22	8.52
e. Intangible assets under development	2.28	-
f. Financial Assets		
(i) Investments	2,819.24	1,540.55
(ii) Other Financial Assets	164.87	161.52
<b>Total Non-current assets</b>	<b>8,440.58</b>	<b>6,620.95</b>
<b>2. Current Assets</b>		
a. Inventories	4,557.10	3,616.96
b. Financial Assets	-	-
(i) Trade receivables	1,865.79	2,100.77
(ii) Cash and cash equivalents	284.01	486.37
c. Current Tax Assets (Net)	5.28	-
d. Other Current Assets	505.23	626.46
<b>Total Current assets</b>	<b>7,217.41</b>	<b>6,830.56</b>
<b>TOTAL ASSETS</b>	<b>15,657.99</b>	<b>13,451.51</b>
<b>II. EQUITY AND LIABILITIES</b>		
<b>A Equity</b>		
a. Equity Share Capital	826.37	826.37
b. Other Equity	12,518.75	10,164.72
<b>TOTAL EQUITY</b>	<b>13,345.12</b>	<b>10,991.09</b>
<b>B Liabilities</b>		
<b>1. Non-Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	45.33	29.90
(ii) Lease liabilities	69.44	113.21
b. Deferred tax liabilities (Net)	137.24	120.75
c. Provisions	148.34	161.51
<b>Total Non-Current Liabilities</b>	<b>400.35</b>	<b>425.37</b>
<b>2. Current Liabilities</b>		
a. Financial Liabilities		
(i) Borrowings	671.76	669.96
(ii) Lease liabilities	43.76	38.10
(iii) Trade payables		
(a) Total outstanding dues of micro enterprise and small enterprises	55.65	-
(b) Total outstanding dues of creditors other than micro enterprises and	281.17	554.97
(iv) Other Financial Liabilities	565.73	493.10
b. Other current liabilities	238.81	242.84
c. Provisions	55.64	33.21
d. Current Tax Liabilities (Net)	-	2.88
<b>Total Current Liabilities</b>	<b>1,912.52</b>	<b>2,035.06</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>15,657.99</b>	<b>13,451.51</b>

For Titan Biotech Limited

[Naresh Kumar Singla]  
 Managing Director  
 DIN-00027448



Place : Delhi  
 Date : 29.05.2024

**TITAN BIOTECH LIMITED**  
**Consolidated Cash Flow Statement for the period ended on 31st March, 2024**

(Rs. in Lakhs.)

Particulars	Year ended	Year ended
	31/03/2024	31/03/2023
	Audited	Audited
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit before Tax	3,152.90	2,811.61
Adjustment for :	-	-
Finance Costs	117.00	74.59
Earlier year Taxes	2.90	3.43
Provision for employees Benefits	32.63	31.23
Depreciation and Amortization Expenses	333.06	260.03
Operating profit before working capital changes	3,638.49	3,180.89
Changes in working Capital:		
Inventories	(940.15)	(148.98)
Trade and other Receivables	352.87	(493.99)
Trade and other Payables	(149.55)	329.86
Cash generation from Operation	2,901.66	2,867.78
Payment of Direct Taxes	(787.03)	(749.95)
<b>Net Cash generated/ (used) - Operating Activities</b>	<b>2,114.63</b>	<b>2,117.83</b>
<b>B. CASH FLOW FROM INVESTMENT ACTIVITIES</b>		
Purchase of Investment in shares	(1,159.71)	(755.50)
Purchase of Property, Plant and Equipment (incl.Capital WIP)	(899.84)	(1,290.46)
Right of use assets	29.18	(26.55)
<b>Net Cash Generated/ (Used) - Investing Activities</b>	<b>(2,030.37)</b>	<b>(2,072.51)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Repayment of Long-term Borrowings	15.44	(78.22)
Repayment of Lease Liabilities	(38.11)	11.49
Proceeds/(Rapyment)of Short-term Borrowings(Net)	1.80	24.94
Finance Cost paid	(117.00)	(74.59)
Dividend paid	(148.75)	(123.96)
<b>Net Cash Generated/ (Used) - Financing Activities</b>	<b>(286.62)</b>	<b>(240.34)</b>
<b>Net Increase/ (Decrease) in Cash and Cash Equivalents</b>	<b>(202.36)</b>	<b>(195.02)</b>
Add : Opening Cash and Cash Equivalents	486.37	681.39
<b>Closing Cash and Cash Equivalents</b>	<b>284.01</b>	<b>486.37</b>

**Notes:**

- The Cash Flow Statements have been prepared under the indirect method as set out in Accounting Standard (AS) on Statement of Cash Flow (Ind AS-7).
- Figures in bracket represent outflows.
- Previous year's figures have been regrouped wherever considered necessary to conform to this year's classification.

For Titan Biotech Limited

  
 [Naresh Kumar Singla]  
 Managing Director  
 DIN-00027448

Place : Delhi  
 Date : 29.05.2024

